Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial

Haemopoietic Stem Cell Transplantation

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Haemopoietic Stem Cell ◽

Open Label Phase ◽

Randomised Controlled ◽

Faculty Opinions recommendation of Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.719895279.793511926 ◽

2015 ◽

Cited By ~ 1

Author(s):

Andrew Gennery

Keyword(s):

Stem Cell ◽

Haemopoietic Stem Cell Transplantation

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Haemopoietic Stem Cell ◽

Open Label Phase ◽

Randomised Controlled ◽

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30452-6 ◽

2020 ◽

Vol 21 (10) ◽

pp. 1317-1330 ◽

Cited By ~ 3

Author(s):

Shaji K Kumar ◽

Susanna J Jacobus ◽

Adam D Cohen ◽

Matthias Weiss ◽

Natalie Callander ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Controlled Trial ◽

Newly Diagnosed ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

SSRN Electronic Journal ◽

10.2139/ssrn.3478102 ◽

2019 ◽

Author(s):

Chiara Cremolini ◽

Carlotta Antoniotti ◽

Daniele Rossini ◽

Sara Lonardi ◽

Fotios Loupakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(19)30723-8 ◽

2019 ◽

Vol 393 (10189) ◽

pp. 2404-2415 ◽

Cited By ~ 233

Author(s):

Brian I Rini ◽

Thomas Powles ◽

Michael B Atkins ◽

Bernard Escudier ◽

David F McDermott ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Safety and effectiveness of intravenous iron sucrose versus standard oral iron therapy in pregnant women with moderate-to-severe anaemia in India: a multicentre, open-label, phase 3, randomised, controlled trial

The Lancet Global Health ◽

10.1016/s2214-109x(19)30427-9 ◽

2019 ◽

Vol 7 (12) ◽

pp. e1706-e1716 ◽

Cited By ~ 6

Author(s):

Sutapa B Neogi ◽

Niveditha Devasenapathy ◽

Ranjana Singh ◽

Himanshu Bhushan ◽

Duru Shah ◽

...

Keyword(s):

Pregnant Women ◽

Controlled Trial ◽

Intravenous Iron ◽

Severe Anaemia ◽

Iron Sucrose ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Faculty Opinions recommendation of Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717950273.793455532 ◽

2012 ◽

Author(s):

Alexander Eggermont

Keyword(s):

Metastatic Melanoma ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00200-4 ◽

2015 ◽

Vol 16 (15) ◽

pp. 1525-1536 ◽

Cited By ~ 86

Author(s):

Alessandro Rambaldi ◽

Anna Grassi ◽

Arianna Masciulli ◽

Cristina Boschini ◽

Maria Caterina Micò ◽

...

Keyword(s):

Stem Cell ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Open Label ◽

Phase 3 ◽

Haemopoietic Stem Cell ◽

Preparative Regimen ◽

Haemopoietic Stem Cell Transplantation ◽

Acute Myeloid

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70549-7 ◽

2014 ◽

Vol 15 (1) ◽

pp. 78-86 ◽

Cited By ~ 290

Author(s):

Hugo E R Ford ◽

Andrea Marshall ◽

John A Bridgewater ◽

Tobias Janowitz ◽

Fareeda Y Coxon ◽

...

Keyword(s):

Controlled Trial ◽

Symptom Control ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(12)60868-x ◽

2012 ◽

Vol 380 (9839) ◽

pp. 358-365 ◽

Cited By ~ 1908

Author(s):

Axel Hauschild ◽

Jean-Jacques Grob ◽

Lev V Demidov ◽

Thomas Jouary ◽

Ralf Gutzmer ◽

...

Keyword(s):

Metastatic Melanoma ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial

The Lancet Haematology ◽

10.1016/s2352-3026(18)30149-2 ◽

2018 ◽

Vol 5 (10) ◽

pp. e479-e492 ◽

Cited By ~ 12

Author(s):

Niels WCJ van de Donk ◽

Bronno van der Holt ◽

Monique C Minnema ◽

Edo Vellenga ◽

Sandra Croockewit ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Controlled Trial ◽

Long Term Results ◽

Phase 3 ◽

Before And After ◽